不同剂量阿托伐汀对不稳定性心绞痛患者的疗效观察

Effect of Different Dosage of Atorvastatin on Patients with Unstable Angina Pectoris

目的探讨不同剂量阿托伐汀对不稳定性心绞痛(UA)患者的调脂疗效,炎症因子水平及临床心脏事件的影响。方法选择在我院门诊就诊的65例UA患者,随机分为三组:常规对照组21例,给予硝酸酯类,阿斯匹林等常规治疗;阿托伐他汀A组22例,在常规治疗基础上给予阿托伐他汀10 mg/d;阿托伐他汀B组22例,给予阿托伐他汀20 mg/d;连续用药8周,分别于给药前及8周末测定血脂水平及血清超敏C-反应蛋白(hsCRP)水平。结果常规对照组给药前后,血脂水平差异无统计学意义(P>0.05)。阿托伐他汀A、B组8周后检测TC、LDC-C水平明显下降(P<0.05)。B组比A组下降更显著。治疗8周后hsCRP水平均明显下降,有统计学意义(P>0.05)。阿托伐他汀A组、B组与常规对照组,B组与A组相比较hsCRP水平下降更显著,有统计学意义(P<0.05)。结论不稳定性心绞痛患者,应用阿托伐他汀治疗后,可以显著降低血脂及炎症因子水平和轻度升高HDL-C,使UA患者受益。

Objective To evaluate the effect of different dosage of Atorvastatin on regulating the lopoid level of patients with unstable angina pectoris, on the level of inflammatory cytokines and clinical cardiac incidents. Methods 65 out - patients with unstable angina pectoris in our hospital were divided into three groups at random：21 patients in this group receiving routine treatment, with the use of nitrates and aspirin; Atorvastatin group A with 22 patients, who were given Atorvastatin 10 mg/d on the basis of routine treatment; Atorvastatin group B with 22 patients, who were given Atorvastatin 20 mg/d. The medicine was used for eight weeks, and then the lopoid level and the High - sensitivity C - reactive protein （hsCRP） were measured before the use of medicine and at the end of the eighth week respectively. Results In the routine treatment group, there was no statistical significance （ P 〉 0.05） in the lopoid level difference before and after the use of medicine; while in Atorvastatin Group A and Group B, the TC, LDL - C level decreased significantly （ P 〈 0.05） after eight weeks. There was a more significant decline in Group B than in Group A. The hs CRP level in both groups dropped greatly after eight weeks＇ treatment, which was statistically significant （ P 〉 0.05）. The hsCRP level in Atorvastatin Group A and Group B decreased more significantly, compared with that in the routine treatment group, which was of statistical significance （ P 〈 0.05）. Conclusion The use of Atorvastatin on patients with unstable angina pectoris can significantly lower lipoid and inflammatory cytokines level, and mildly increase HDL - C, which can benefit the patients with unstable angina pectoris.